Biovail founder concedes defeat

Biovail founder Eugene Melnyk is giving up the fight. After dogging the company for months--and winning a court order requiring shareholders to re-vote on his proposals--Melnyk said he was abandoning his plan to kick out Biovail's board of directors to bring in his own management. Instead, he'll push forward with plans to start his own drug company.

Analysts weren't totally surprised by the move, even though it came shortly after his court victory last week. "He didn't have a lot of momentum," one said. "Even with the court's decision there wasn't a lot going in his favor and he can't have expected a huge swing in his direction."

Biovail management has to be breathing a sigh of relief. Between regulators and Melnyk, the company has had plenty to contend with lately.

- see the New York Times story

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.